Spermine-Functionalized Multiepitope Signaling Peptide Nanovaccine to Stimulate the Systemic Immunity against Pneumonia

IF 3.7 Q1 CHEMISTRY, MEDICINAL
Arivalagan Ponbharathi, Sivaraj Mehnath, Chithaiyan Kamaladevi Sowndharya, Kannaiyakumar Dharshini, Ammavasi Chandran Ambigaibalan and Murugaraj Jeyaraj*, 
{"title":"Spermine-Functionalized Multiepitope Signaling Peptide Nanovaccine to Stimulate the Systemic Immunity against Pneumonia","authors":"Arivalagan Ponbharathi,&nbsp;Sivaraj Mehnath,&nbsp;Chithaiyan Kamaladevi Sowndharya,&nbsp;Kannaiyakumar Dharshini,&nbsp;Ammavasi Chandran Ambigaibalan and Murugaraj Jeyaraj*,&nbsp;","doi":"10.1021/acsptsci.5c00328","DOIUrl":null,"url":null,"abstract":"<p >Pneumonia is a high-risk chronic respiratory infection with serious morbidity and mortality rates. Existing vaccines have a poor immune response; vaccine efficiency is limited to the specific serotypes, indicating an urgent need to develop an effective vaccine. The study pursues to design multiepitope signaling peptide nanovaccine using the YSIRK-G/S motif, B/T-cell epitope, and surface modification of the dextran (Dex), functionalized with spermine. It improves the higher load of signaling peptide motif (SPM), pH-responsive delivery, immune cell targeting, endosomal escape, higher antigenicity, and immune activation. The surface modification of dextran enhances nanoparticle uptake, and spermine functionalization regulates particle aggregation. Spermine-modified acetalated dextran nanoparticles (AcDx-Sp NPs) show a higher loading of SPM and uniform spherical morphology with a size range of 105 nm. After impregnation of SPM, the nanovaccine was stable and maintained the structural integrity for 3 days in both PBS and DMEM. In acidic pH conditions, the nanovaccine destabilized to release SPM in 65% in 5 days; at pH 5.0, AcDx was degraded into Dex, providing endosomal escape and releasing the SPM. In vitro studies show the activation of dendritic cells (DCs) and upregulation up to a 200-fold increase in pro-inflammatory cytokine compared to SPM. Comparatively, mice after immunization elicited higher antibody titers and stimulated the robust CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses, alongside strong IgA and IgG production. Serum bacterial neutralization assay confirms the high amount of antibody production, and it is able to neutralize the bacteria, which was confirmed through confocal and HRTEM analysis. This potent neutralization capability underscores the therapeutic promise of these antibodies for controlling bacterial pathogenesis. Overall, nanovaccine was potentially targeting the antigen-presenting cells (APCs), inherent adjuvant function, and peptides providing systemic immunity.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 9","pages":"3182–3198"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.5c00328","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Pneumonia is a high-risk chronic respiratory infection with serious morbidity and mortality rates. Existing vaccines have a poor immune response; vaccine efficiency is limited to the specific serotypes, indicating an urgent need to develop an effective vaccine. The study pursues to design multiepitope signaling peptide nanovaccine using the YSIRK-G/S motif, B/T-cell epitope, and surface modification of the dextran (Dex), functionalized with spermine. It improves the higher load of signaling peptide motif (SPM), pH-responsive delivery, immune cell targeting, endosomal escape, higher antigenicity, and immune activation. The surface modification of dextran enhances nanoparticle uptake, and spermine functionalization regulates particle aggregation. Spermine-modified acetalated dextran nanoparticles (AcDx-Sp NPs) show a higher loading of SPM and uniform spherical morphology with a size range of 105 nm. After impregnation of SPM, the nanovaccine was stable and maintained the structural integrity for 3 days in both PBS and DMEM. In acidic pH conditions, the nanovaccine destabilized to release SPM in 65% in 5 days; at pH 5.0, AcDx was degraded into Dex, providing endosomal escape and releasing the SPM. In vitro studies show the activation of dendritic cells (DCs) and upregulation up to a 200-fold increase in pro-inflammatory cytokine compared to SPM. Comparatively, mice after immunization elicited higher antibody titers and stimulated the robust CD4+ and CD8+ T-cell responses, alongside strong IgA and IgG production. Serum bacterial neutralization assay confirms the high amount of antibody production, and it is able to neutralize the bacteria, which was confirmed through confocal and HRTEM analysis. This potent neutralization capability underscores the therapeutic promise of these antibodies for controlling bacterial pathogenesis. Overall, nanovaccine was potentially targeting the antigen-presenting cells (APCs), inherent adjuvant function, and peptides providing systemic immunity.

Abstract Image

精胺功能化多表位信号肽纳米疫苗刺激肺炎全身免疫
肺炎是一种高风险的慢性呼吸道感染,发病率和死亡率都很高。现有疫苗的免疫反应较差;疫苗的效力仅限于特定的血清型,这表明迫切需要开发有效的疫苗。本研究旨在利用YSIRK-G/S基序、B/ t细胞表位和精胺功能化的右旋糖酐(Dex)的表面修饰设计多表位信号肽纳米疫苗。它提高了信号肽基序(SPM)的高负荷、ph响应递送、免疫细胞靶向、内体逃逸、更高的抗原性和免疫激活。右旋糖酐的表面修饰增强了纳米颗粒的吸收,精胺功能化调节了纳米颗粒的聚集。精胺修饰的乙酰化葡聚糖纳米粒子(AcDx-Sp NPs)具有较高的SPM负载和均匀的球形形貌,尺寸范围为105 nm。SPM浸渍后,纳米疫苗在PBS和DMEM中均保持了3天的稳定性和结构完整性。在酸性pH条件下,纳米疫苗在5天内稳定释放65%的SPM;在pH 5.0时,AcDx降解为Dex,提供内体逃逸并释放SPM。体外研究表明,与SPM相比,树突状细胞(dc)的活化和促炎细胞因子的上调高达200倍。相比之下,免疫后的小鼠产生更高的抗体滴度,刺激强劲的CD4+和CD8+ t细胞反应,同时产生强大的IgA和IgG。血清细菌中和实验证实抗体产生量高,能够中和细菌,共聚焦和HRTEM分析证实了这一点。这种有效的中和能力强调了这些抗体在控制细菌发病机制方面的治疗前景。总的来说,纳米疫苗潜在地靶向抗原呈递细胞(APCs)、固有的佐剂功能和提供全身免疫的肽。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Pharmacology and Translational Science
ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)
CiteScore
10.00
自引率
3.30%
发文量
133
期刊介绍: ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信